Literature DB >> 7519642

Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES.

M Ebisawa1, T Yamada, C Bickel, D Klunk, R P Schleimer.   

Abstract

Selective eosinophil recruitment occurs after experimental Ag challenge and in tissue sites of allergic diseases. The mechanisms of selective eosinophil migration are still unknown. In our study, we examined the ability of chemokines to induce transendothelial migration (TEM) of eosinophils in vitro. Among the chemokines tested, only RANTES induced eosinophil TEM. RANTES failed to induce TEM of neutrophils. Interestingly, IL-8 induced neutrophil TEM and had no effect on eosinophil TEM. RANTES-induced TEM was concentration-dependent and was inhibited by Abs directed against the beta 2 integrin CD18. When IL-1-activated endothelial cells were utilized, RANTES-induced TEM also involved the eosinophil beta 1 integrin VLA-4. RANTES did not increase eosinophil adhesion to either resting or IL-1-activated endothelial cells, nor did the chemokine increase CD11b or decrease L-selectin expression. A gradient of RANTES appears to be required for eosinophil TEM. Pre-exposure of eosinophils to IL-5 dramatically potentiated the TEM response to RANTES. These findings suggest that the chemokine RANTES is a potent and selective inducer of eosinophil TEM. Because RANTES appears to be produced in vivo during allergic reactions or in allergic diseases, we speculate that these findings may have some direct relevance to the mechanism of selective eosinophil recruitment in vivo in humans.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519642

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Chemokines in the limbal form of vernal keratoconjunctivitis.

Authors:  A M Abu El-Asrar; S Struyf; S A Al-Kharashi; L Missotten; J Van Damme; K Geboes
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

2.  Neutrophils, lymphocytes, and monocytes exhibit diverse behaviors in transendothelial and subendothelial migrations under coculture with smooth muscle cells in disturbed flow.

Authors:  Cheng-Nan Chen; Shun-Fu Chang; Pei-Ling Lee; Kyle Chang; Li-Jing Chen; Shunichi Usami; Shu Chien; Jeng-Jiann Chiu
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

Review 3.  Allergic Respiratory Inflammation and Remodeling.

Authors:  Kawa A M Amin
Journal:  Turk Thorac J       Date:  2015-07-01

4.  The C-C chemokine receptor CCR3 participates in stimulation of eosinophil arrest on inflammatory endothelium in shear flow.

Authors:  J Kitayama; C R Mackay; P D Ponath; T A Springer
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

Review 5.  Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors.

Authors:  W J Metzger
Journal:  Springer Semin Immunopathol       Date:  1995

Review 6.  Chemokines and tissue injury.

Authors:  M B Furie; G J Randolph
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

7.  Contrasting roles for RANTES and macrophage inflammatory protein-1 alpha (MIP-1 alpha) in a murine model of allergic peritonitis.

Authors:  A M Das; M N Ajuebor; R J Flower; M Perretti; S R McColl
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 8.  Monocyte chemoattractant protein-1 (MCP-1): an overview.

Authors:  Satish L Deshmane; Sergey Kremlev; Shohreh Amini; Bassel E Sawaya
Journal:  J Interferon Cytokine Res       Date:  2009-06       Impact factor: 2.607

9.  Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils.

Authors:  C Weber; J Kitayama; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  Relationship between eosinophilia and levels of chemokines (CCL5 and CCL11) and IL-5 in bronchoalveolar lavage fluid of patients with mustard gas-induced pulmonary fibrosis.

Authors:  Ali Emad; Yasaman Emad
Journal:  J Clin Immunol       Date:  2007-06-28       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.